Can You Take Peptides While Pregnant or Breastfeeding? No

Pregnancy is not a steady state with a passenger. Maternal insulin sensitivity falls through the second and third trimesters, visceral adipose tissue increases as a normal physiologic change, growth hormone and IGF-1 signaling shift, and appetite and gastric motility change on their own. The FDA-approved tesamorelin labeling makes the point for its own molecule: visceral adipose tissue increases during pregnancy because of normal metabolic and hormonal changes, and modifying that offers no known benefit and could result in fetal harm. A peptide whose purpose is to push one of those dials is acting on a system the pregnancy is already remodeling.

This is the most common misunderstanding, and the approved labeling addresses it plainly. The FDA-approved semaglutide labeling for weight management states that weight loss offers no benefit to a pregnant patient and may cause fetal harm, and directs that the medication be discontinued in pregnant patients using it for weight reduction. The approved tirzepatide labeling says the same, and adds that appropriate weight gain based on pre-pregnancy weight is recommended for all pregnant patients, including those who already have obesity or overweight, because of the obligatory weight gain in maternal tissues. Weight before pregnancy is a legitimate clinical question, and treating it before trying to conceive is reasonable. The medication stops before conception rather than continuing into the pregnancy.

Oxytocin causes most of the confusion. Oxytocin is a peptide, it is FDA approved, and it is used in pregnancy — as a controlled intravenous infusion in hospital, titrated to uterine response, for the initiation or improvement of uterine contractions where delivery is indicated, and after delivery to control postpartum bleeding. That labeling states explicitly that it is not indicated for elective induction of labor, because the available data are inadequate to evaluate the benefits-to-risks considerations. A supervised inpatient infusion with a defined obstetric indication has almost nothing in common with an elective subcutaneous oxytocin prescription for intimacy and connection, which is what oxytocin is on this site.

Kisspeptin is the second example. Kisspeptin-54 has been studied in humans as a trigger for oocyte maturation in IVF cycles, including work in the Journal of Clinical Investigation in 2014 and the Journal of Clinical Endocrinology and Metabolism in 2015. That is a single dose at a defined point in a monitored cycle, not evidence that ongoing kisspeptin dosing is appropriate during a pregnancy.

The approved semaglutide labeling for weight management carries this in its Highlights and again in the Females and Males of Reproductive Potential section: because of the potential for fetal harm, discontinue the medication at least 2 months before a planned pregnancy, to account for the long half-life of semaglutide. The approved semaglutide labeling for type 2 diabetes carries the same two-month instruction, worded as discontinuation at least 2 months before a planned pregnancy due to the long washout period.

Two months rather than two weeks because of how slowly semaglutide clears; it is a weekly injection precisely because it persists. The practical consequence is that the conversation cannot happen after conception — by the time a test is positive, the window has passed.

The Risk Summary is careful and worth reading as written. Based on animal reproduction studies, there may be potential risks to the fetus from exposure to semaglutide during pregnancy. Available pharmacovigilance and clinical trial data in pregnant patients are described as insufficient to establish a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes, and when a pregnancy is recognized the labeling directs that the patient be advised of the risk to a fetus and that the medication be discontinued where it is used for weight reduction. "Insufficient to establish a risk" is not "no risk." It is the regulatory phrasing for not enough data to say either way.

The evidence behind the caution is animal data. In pregnant rats given semaglutide during organogenesis, structural abnormalities and alterations to growth were reported at clinically relevant maternal exposures; in rabbits, early pregnancy losses and minor visceral and skeletal fetal abnormalities; in cynomolgus monkeys, sporadic skeletal abnormalities. In each species the findings coincided with marked maternal body weight loss, the pharmacologically expected effect of the drug. That the findings track the drug's intended effect makes them mechanistically coherent, which is worse, not better.

The approved tirzepatide labeling does not carry a two-month pre-pregnancy interval. It instructs that pregnant patients be advised weight loss is not recommended during pregnancy and that tirzepatide be discontinued when a pregnancy is recognized, with the same statement that available data in pregnant patients are insufficient to evaluate a drug-related risk. Its animal data follows the semaglutide pattern: in pregnant rats given tirzepatide during organogenesis, increased incidences of external, visceral and skeletal malformations, developmental variations and decreased fetal weights, coinciding with reductions in maternal body weight and food consumption.

The absence of a stated interval is not permission to time it more tightly. Your physician sets one on the same reasoning: a weekly agent with slow clearance, stopped well before conception rather than at a positive test.

This is the point most people have never heard, and it appears three times in the approved tirzepatide labeling. Tirzepatide delays gastric emptying, and that delay may reduce the efficacy of oral hormonal contraceptives. The labeling advises patients using oral hormonal contraceptives to switch to a non-oral method, or to add a barrier method, for 4 weeks after initiating tirzepatide and for 4 weeks after each dose escalation. The delay is described as largest after the first dose and as diminishing over time, and hormonal contraceptives not administered orally are described as not affected. The approved tirzepatide labeling for type 2 diabetes carries the identical instruction.

The second half is the part people miss: not only the first four weeks, but four weeks after each dose escalation, and a tirzepatide titration has several. Three things then line up badly — the person is early in treatment and focused on nausea rather than contraception, the escalations feel like non-events, and weight loss itself can restore ovulation in someone who had assumed their fertility was low.

Both molecules have registries, because the pre-approval trials could not answer the question. The approved semaglutide labeling describes a pregnancy exposure registry monitoring outcomes in women exposed during pregnancy, and the approved tirzepatide labeling describes an equivalent registry with its own contact route. If you became pregnant while taking either, your physician can tell you how to enroll.

Compounded semaglutide and tirzepatide share the active ingredient with the approved products but are not those products, and compounded medications are not FDA approved as finished drug products. That cuts one way only: the approved labeling is the best available information about the molecule, so a prescriber applies it. The absence of a label for a compounded preparation removes a document, not a risk.

The approved semaglutide labeling states there are no data on the presence of subcutaneously administered semaglutide or its metabolites in human milk, no data on effects on the breastfed infant, and no data on effects on milk production, and directs that the benefits of breastfeeding be weighed against the mother's clinical need. The diabetes labeling adds that semaglutide was present in the milk of lactating rats at levels three- to twelve-fold lower than in maternal plasma, while noting that species differences make the clinical relevance unclear.

The tablet presentation shows how a lactation caution can arise from an excipient rather than the peptide. In a clinical lactation study with the oral semaglutide tablet, semaglutide in human milk was below the lower limit of quantification — but SNAC, the absorption enhancer, and/or its metabolites are present in human milk, and because the enzymes that clear SNAC may be less active in infants, the labeling advises that breastfeeding is not recommended during treatment with the tablet.

Tirzepatide has the most specific human lactation data here. In a single-dose study, 11 healthy lactating adults received a single 5 mg dose; tirzepatide was undetectable in 164 of 171 breast milk samples assayed, and the cumulative amount in the remaining seven over a 28-day window was equivalent to less than 0.02% of the maternal administered dose. The labeling still states there are no available data on effects on the breastfed infant or on milk production. That is real data and it is reassuring about transfer, but transfer and effect are different questions and the second has not been studied.

The approved tesamorelin labeling states there are no data on the presence of tesamorelin in human milk, the effects on a breastfed child, or the effects on milk production, and advises that mothers should not breastfeed while receiving it.

For BPC-157, TB-500, GHK-Cu, KPV, sermorelin, ipamorelin, CJC-1295, IGF-1 LR3, PT-141, kisspeptin, Semax, Selank, DSIP, epithalon, MOTS-c and the blends built from them there is no human lactation data of any kind, because there is no approved product to carry a label. Lactation also raises energy and micronutrient requirements substantially, so a medication whose mechanism is to reduce food intake works against that regardless of whether any molecule reaches the infant.

Sermorelin, ipamorelin, CJC-1295 and tesamorelin prompt the pituitary to release growth hormone, which raises IGF-1. The human evidence outside pregnancy is real — sermorelin has decades of endocrine literature in the Journal of Clinical Endocrinology and Metabolism, tesamorelin has randomized trials in the New England Journal of Medicine in 2007 and JAMA in 2014 in people with HIV-associated visceral fat accumulation, and ipamorelin was characterized as a selective growth hormone secretagogue in the European Journal of Endocrinology in 1998. None of it included pregnancy.

Tesamorelin is the one member of this group with an FDA-approved counterpart, and that label is explicit: contraindicated in pregnant women, and discontinued if a patient becomes pregnant while taking it. Where one member of a class carries an approved contraindication, the reading for the rest is not "the others are fine."

BPC-157, TB-500, GHK-Cu and KPV sit on an evidence base that is largely preclinical even outside pregnancy. The BPC-157 literature is animal and cell work — Achilles tendon detachment in rats in the Journal of Orthopaedic Research in 2006, growth hormone receptor expression in cultured tendon fibroblasts in Molecules in 2014, gastrointestinal work reviewed in Current Pharmaceutical Design. There are no large randomized controlled trials of BPC-157 in humans and no pregnancy data at all. The same holds for GHK-Cu, whose literature runs from FEBS Letters in 1988 on collagen synthesis in cultured fibroblasts through modern gene-expression work, none of it in pregnancy. A mechanism described around angiogenesis and tissue remodeling is not one to introduce electively into a pregnancy, which involves a great deal of both.

IGF-1 LR3 is the most direct growth signal in the catalog. The IGF-1 literature, including the systematic review of IGF-1, IGFBP-3 and cancer risk in the Lancet in 2004, concerns a signal that drives cell proliferation. IGF-1 LR3 is not used in pregnancy.

PT-141 is bremelanotide, the rare case here where an FDA-approved version exists and the pregnancy section contains human numbers. That labeling reports 7 pregnancies among more than 1,057 patients treated for up to 12 months, with no major congenital anomalies reported among them. It also reports that subcutaneous bremelanotide in pregnant dogs during organogenesis at exposures at or above 16 times the maximum recommended human dose produced fetal harm, and that developmental effects were observed in mouse offspring at exposures at or above 125 times. Because the lowest dose associated with fetal harm was not identified in either species, the labeling directs that women use effective contraception while taking it, discontinue it if pregnancy is suspected, and states that use in pregnancy is not recommended.

Seven pregnancies is not a safety dataset, and the labeling treats it as insufficient. Anyone considering PT-141 while trying to conceive should read it the same way. For oxytocin and kisspeptin, supervised obstetric or fertility-clinic uses exist, and neither is used as ongoing elective therapy in pregnancy.

Semax, Selank, DSIP, PE-22-28 and Dihexa have no human pregnancy or lactation data, and the research behind them was conducted entirely in non-pregnant populations.

Vitamin and metabolic injectables deserve an honest distinction. Methylcobalamin is a form of vitamin B12, a required nutrient in pregnancy and a routine part of prenatal supplementation — the substance is not the problem, the elective injectable program is, because nutritional requirements in pregnancy are managed through prenatal care with its own protocols. NAD+, glutathione, L-carnitine and the lipotropic injections are not vitamins in that sense and have no pregnancy data as injectables. Melanotan II has none either, and its wider literature includes a review of the risks of unregulated use of alpha-melanocyte-stimulating hormone analogues in the International Journal of Dermatology in 2017. In every case the injectable program stops and the prenatal team takes over.